San Diego, CA—Sun Genomics, a personalized nutrition company that makes custom gut probiotics tailored and formulated to customers’ unique microflora, announced the close of $9.25 million in Series A funding. The round was led by Pangaea Ventures with new investments from Orion Fund, managed by K3 Ventures, and Emerging Technologies Partners. Additional investors include Danone Manifesto Ventures, SOSV, Human Longevity, and Nascita Ventures.
Founded in 2016, Sun Genomics offers a microbiome test and gut probiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a personalized product based on their unique gut profiles. According to the release, this new round of funding will be used to support the company’s growth in the custom probiotics market, scale delivery across the U.S., enter international markets, and propel the publication of its studies in partnership with academic institutions.
“Among the scientific and general community, the awareness and understanding of the gut microflora’s important impact on a person’s overall health and well-being is growing rapidly,” said MX Kuok, Managing Partner of K3 Ventures, in a press release from Sun Genomics. “We are proud to support Sun Genomics’ scientifically rigorous approach to microbiome sequencing and customized probiotics, which has already improved lives in a quantifiable, measurable way.”
Sunny Jain, CEO and Founder of Sun Genomics, added, “Despite the many challenges and setbacks the pandemic has had on businesses and individuals, we’re proud of the momentum we’ve built this year from this new financing, to a prestigious academic collaboration, and the launch of our innovative immunity-health supplement, Floré Defense.”